What happened
Identification of C3 as a target of Genistein, Isotretinoin and Rofecoxib in age-related macular degeneration
SourceElsevier BVpublicationBiotech
Identification of C3 as a target of Genistein, Isotretinoin and Rofecoxib in age-related macular degeneration
Publication signal: Identification of C3 as a target of Genistein, Isotretinoin and Rofecoxib in age-related macular degeneration
Factual summary
Why it matters
Recent source-backed research output for AISci Stage A browsing.
SourceElsevier BVLimitations
AISci rank score does not assess scientific quality or citation impact.
SourceElsevier BVLinked output
Identification of C3 as a target of Genistein, Isotretinoin and Rofecoxib in age-related macular degenerationpaperPeople
No reviewed person relationship is attached to this event.
Organizations
No reviewed organization relationship is attached to this event.
Topics
Problems
No reviewed problem relationship is attached to this event.
Relationship evidence
Protein and Drug Design
Controlled AISci Stage A topic for Protein and Drug Design.
Identification of C3 as a target of Genistein, Isotretinoin and Rofecoxib in age-related macular degeneration
Identification of C3 as a target of Genistein, Isotretinoin and Rofecoxib in age-related macular degeneration
Timeline
- publicationIdentification of C3 as a target of Genistein, Isotretinoin and Rofecoxib in age-related macular degeneration